Amgen to acquire small-molecule therapies developer Rodeo
Rodeo’s preclinical programme targeting 15-PGDH will support Amgen in developing therapeutic agents against inflammatory disease indications
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Mar 21
Rodeo’s preclinical programme targeting 15-PGDH will support Amgen in developing therapeutic agents against inflammatory disease indications
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Mar 21
GSK will support the manufacturing of up to 60 million doses of Novavax’s Covid-19 vaccine at its Barnard…
29 Mar 21
VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal antibody intended for treating mild-to-moderate Covid-19
26 Mar 21
Breyanzi is a chimeric antigen receptor (CAR) T cell therapy designed to target CD19, a biomarker for normal…
26 Mar 21
The Phase 1/2/3 trial will evaluate two-dose mRNA vaccine BNT162b2, administered 21 days apart, in three age groups
25 Mar 21
The analysis confirmed that the AZD1222 vaccine is 76% effective against symptomatic Covid-19, and 100% against severe disease…
23 Mar 21
AZD1222 showed 79% vaccine efficacy in preventing symptomatic Covid-19 and 100% efficacy against severe Covid-19 and hospitalisation
22 Mar 21
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that keeps lymphocytes out of the blood
22 Mar 21
The new Covid-19 vaccine candidate is a virus like particle (VLP) triple antigen vaccine, which offers triple protection…
19 Mar 21
The new large-scale cell culture manufacturing facility in Holly Springs, North Carolina will create 725 jobs in the…